The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

Table 4 Whole brain atrophy rates for subjects treated with placebo or galantamine, stratified according to apolipoprotein E genotype

	Placebo	Galantamine	Adjusted mean difference	95% CI
APOE ϵ4 noncarriers	0.48	0.41	0.07	−0.10; 0.25
APOE ϵ4 carriers	0.77	0.49	0.28	0.07; 0.50

Data presented as percentage change per year. The numbers of subjects per cell were as follows: APOE ϵ4 noncarriers, total n = 109 (placebo, n = 54; galantamine, n = 55), APOE ϵ4 carriers, total n = 97 (placebo, n = 54; galantamine, n = 43). APOE, apolipoprotein E; CI, confidence interval.